**Breast**

**Triple negative breast cancer (TNBC)**
- Early stage TNBC
  - Neoadjuvant
    - 10013: Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)
  - First line
    - ▼ 9876: Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer
    - 10146: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
  - Later Line
    - ▼ 9881: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)
    - ▼ 10031: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (Currently in dose escalation)

**ER+/HER2- breast cancer**
- Locally advanced/metastatic TNBC
  - First or second line
    - ▼ 9844: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors (In expansion cohort)
    - ▼ 10131: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Currently in dose escalation. Expansion cohorts include breast, prostate, and other solid tumors.)

**TNBC or ER+/HER2- breast cancer**
- Locally advanced/metastatic ER+/HER2-
  - First or second line
    - ▼ 10287: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)

**TNBC or ER+/HER2- breast cancer**
- Locally advanced/metastatic ER+/HER2-
  - Later line
    - ▼ 10195: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

**PTEN or PIK3CB mutation**
- Later line
  - ▼ 9884: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors (In expansion cohort)

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: 11/12/2018